Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 4/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160791 | 0.94 | HTR1D (0.36) | HTR1DHTR1BPREP | |
| SCHEMBL6058554 | 0.85 | PREP (0.34) | HTR1DHTR1BPREP | |
| SCHEMBL6705270 | 0.78 | PREP (0.44) | PREPPDK2NOTUMKDM4EALDH1A1 | |
| Biphenyl SCHEMBL7167410 | 0.74 | PREP (0.40) | PREPPDK2NOTUMALDH1A1 | |
| SCHEMBL6701789 | 0.69 | HPGD (0.47) | PREPKDM4EALDH1A1 | |
| SCHEMBL8906116 | 0.69 | CA1 (0.56) | PREPNOTUMKDM4EALDH1A1 | |
| SCHEMBL6058804 | 0.67 | PREP (0.46) | PREP | |
| SCHEMBL18304558 | 0.66 | KDM4E (0.44) | NOTUMKDM4EALDH1A1 | |
| SCHEMBL6625609 | 0.66 | KDM4E (0.44) | PREPNOTUMKDM4EALDH1A1 | |
| SCHEMBL20487829 | 0.66 | KDM4E (0.39) | PREPNOTUMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | HTR1D 1815/4885HTR1B 503/4885PREP 3168/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | HTR1D 1398/4885HTR1B 886/4885PREP 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.